BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Jan 13, 2020
Company News

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease. Monday’s deal is Biogen’s second in...
BioCentury | Aug 17, 2017
Clinical News

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) reported data from 24 heavily treated patients with advanced solid tumors in the dose-escalation part 1 of a Phase I trial showing that 8-288 mg/m 2 /day doses of CYC065 given...
BioCentury | Apr 27, 2017
Clinical News

CYC140: Preclinical data

In mouse xenograft models of esophageal cancer and acute leukemia, CYC140 significantly reduced mean tumor volume vs. vehicle-treated controls. Data were presented at the American Association for Cancer Research meeting in Washington, D.C. CYC140 is...
BioCentury | Apr 13, 2017
Clinical News

CYC065: Preclinical data

In vitro , CYC065 inhibited growth, triggered apoptosis and induced anaphase catastrophe in murine and human lung cancer cells with known high metastatic potential. CYC065 also inhibited migration and invasion of lung cancer cells. Data were...
BioCentury | Feb 24, 2017
Clinical News

Sapacitabine: Additional Ph III SEAMLESS data

The open-label, international Phase III SEAMLESS trial in 491 newly diagnosed AML patients ages ≥70 years who were not candidates for, or who refused, intensive induction chemotherapy showed that alternating cycles of sapacitabine and Dacogen...
BioCentury | Feb 23, 2017
Clinical News

Cyclacel's sapacitabine fails in Phase III AML trial

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine ( CYC682 ) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute myelogenous leukemia in elderly...
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

Infectious disease INDICATION: Viral infection Cell culture studies suggest the pan-caspase inhibitor emricasan, the generic antihelminthic niclosamide or CDK inhibitors could help treat Zika. In a Zika virus-infected human glioblastoma cell line, screening of 6,000...
BioCentury | Nov 16, 2015
Clinical News

CYC065: Phase I started

Cyclacel began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral CYC065 every 3 weeks in about 35 patients. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Product: CYC065 Business: Cancer Molecular target: Cyclin dependent...
BioCentury | Aug 24, 2015
Clinical News

Seliciclib: Phase II started

Cyclacel said investigators began an open-label, U.S. Phase II trial to evaluate 400 mg oral seliciclib twice daily for 4 days every week for 4 weeks in about 16 patients with de novo, persistent or...
Items per page:
1 - 10 of 164